Coherus Oncology, Inc. (CHRS)

US — Healthcare Sector
Peers: CTMX  NUVB  ASMB  LYRA  ATRA  FGEN  MGNX  BPMC 

Automate Your Wheel Strategy on CHRS

With Tiblio's Option Bot, you can configure your own wheel strategy including CHRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CHRS
  • Rev/Share 1.23
  • Book/Share 1.0323
  • PB 1.6468
  • Debt/Equity 0.0201
  • CurrentRatio 1.4422
  • ROIC 0.9659

 

  • MktCap 197586368.0
  • FreeCF/Share -0.912
  • PFCF -1.8664
  • PE 1.0978
  • Debt/Assets 0.0055
  • DivYield 0
  • ROE -2.5352

 

  • Rating A+
  • Score 4
  • Recommendation Buy
  • P/E Score 3
  • DCF Score 5
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade CHRS Maxim Group Hold Buy -- -- Sept. 4, 2025
Downgrade CHRS UBS Buy Neutral $4 $1.5 Aug. 16, 2024

News

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
CHRS
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – – CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –

Read More
image for news Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Coherus Oncology: Five Readouts Or More Possible In 2026
CHRS
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Neutral

Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. The company could report readouts from its drugs in three indications in H1 2026: casdozokitug in hepatocellular carcinoma, CHS-114 in gastric cancer, and CHS-114 in head and neck cancer. There could be further readouts from CHS-114 in 2026 in esophageal squamous cell carcinoma and colorectal cancer.

Read More
image for news Coherus Oncology: Five Readouts Or More Possible In 2026

About Coherus Oncology, Inc. (CHRS)

  • IPO Date 2014-11-06
  • Website https://www.coherus.com
  • Industry Biotechnology
  • CEO Dennis M. Lanfear
  • Employees 228
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.